Beyond pancreatic cancer

Irinotecan and gemcitabine in solid tumors and hematologic malignancies

C. M S Rocha Lima, J. J. Urbanic, A. Lal, R. Kneuper-Hall, C. Y. Brunson, M. R. Green

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Non-platinum combinations including gemcitabine and irinotecan (Gemzar; Eli Lilly and Company, Indianapolis, IN) for the management of a variety of malignancies have started to emerge. Gemcitabine and irinotecan are well-tolerated single agents, each with a broad spectrum of antitumor activity. Preclinical data suggests synergy for the two drugs when used in combination. A phase I trial has defined a well-tolerated combination regimen using both drugs on a day-1, -8 schedule every 3 weeks. Phase II data suggest activity for the combination in pancreatic cancer, and a phase III trial of the two-drug combination versus gemcitabine alone is underway in previously untreated pancreatic cancer patients. Other phase II trials evaluating the impact of this combination on a variety of other tumors, such as non-small cell lung, small cell lung, breast, colorectal, and non-Hodgkin's lymphoma, are either forthcoming or in progress.

Original languageEnglish
Pages (from-to)34-43
Number of pages10
JournalSeminars in Oncology
Volume28
Issue number3 SUPPL. 10
StatePublished - Aug 29 2001

Fingerprint

irinotecan
gemcitabine
Hematologic Neoplasms
Pancreatic Neoplasms
Neoplasms
Lung
Drug Combinations
Pharmaceutical Preparations
Non-Hodgkin's Lymphoma
Appointments and Schedules
Breast

ASJC Scopus subject areas

  • Oncology

Cite this

Rocha Lima, C. M. S., Urbanic, J. J., Lal, A., Kneuper-Hall, R., Brunson, C. Y., & Green, M. R. (2001). Beyond pancreatic cancer: Irinotecan and gemcitabine in solid tumors and hematologic malignancies. Seminars in Oncology, 28(3 SUPPL. 10), 34-43.

Beyond pancreatic cancer : Irinotecan and gemcitabine in solid tumors and hematologic malignancies. / Rocha Lima, C. M S; Urbanic, J. J.; Lal, A.; Kneuper-Hall, R.; Brunson, C. Y.; Green, M. R.

In: Seminars in Oncology, Vol. 28, No. 3 SUPPL. 10, 29.08.2001, p. 34-43.

Research output: Contribution to journalArticle

Rocha Lima, CMS, Urbanic, JJ, Lal, A, Kneuper-Hall, R, Brunson, CY & Green, MR 2001, 'Beyond pancreatic cancer: Irinotecan and gemcitabine in solid tumors and hematologic malignancies', Seminars in Oncology, vol. 28, no. 3 SUPPL. 10, pp. 34-43.
Rocha Lima CMS, Urbanic JJ, Lal A, Kneuper-Hall R, Brunson CY, Green MR. Beyond pancreatic cancer: Irinotecan and gemcitabine in solid tumors and hematologic malignancies. Seminars in Oncology. 2001 Aug 29;28(3 SUPPL. 10):34-43.
Rocha Lima, C. M S ; Urbanic, J. J. ; Lal, A. ; Kneuper-Hall, R. ; Brunson, C. Y. ; Green, M. R. / Beyond pancreatic cancer : Irinotecan and gemcitabine in solid tumors and hematologic malignancies. In: Seminars in Oncology. 2001 ; Vol. 28, No. 3 SUPPL. 10. pp. 34-43.
@article{e312aa96fa6d418abfcbe1c5814b7d52,
title = "Beyond pancreatic cancer: Irinotecan and gemcitabine in solid tumors and hematologic malignancies",
abstract = "Non-platinum combinations including gemcitabine and irinotecan (Gemzar; Eli Lilly and Company, Indianapolis, IN) for the management of a variety of malignancies have started to emerge. Gemcitabine and irinotecan are well-tolerated single agents, each with a broad spectrum of antitumor activity. Preclinical data suggests synergy for the two drugs when used in combination. A phase I trial has defined a well-tolerated combination regimen using both drugs on a day-1, -8 schedule every 3 weeks. Phase II data suggest activity for the combination in pancreatic cancer, and a phase III trial of the two-drug combination versus gemcitabine alone is underway in previously untreated pancreatic cancer patients. Other phase II trials evaluating the impact of this combination on a variety of other tumors, such as non-small cell lung, small cell lung, breast, colorectal, and non-Hodgkin's lymphoma, are either forthcoming or in progress.",
author = "{Rocha Lima}, {C. M S} and Urbanic, {J. J.} and A. Lal and R. Kneuper-Hall and Brunson, {C. Y.} and Green, {M. R.}",
year = "2001",
month = "8",
day = "29",
language = "English",
volume = "28",
pages = "34--43",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 10",

}

TY - JOUR

T1 - Beyond pancreatic cancer

T2 - Irinotecan and gemcitabine in solid tumors and hematologic malignancies

AU - Rocha Lima, C. M S

AU - Urbanic, J. J.

AU - Lal, A.

AU - Kneuper-Hall, R.

AU - Brunson, C. Y.

AU - Green, M. R.

PY - 2001/8/29

Y1 - 2001/8/29

N2 - Non-platinum combinations including gemcitabine and irinotecan (Gemzar; Eli Lilly and Company, Indianapolis, IN) for the management of a variety of malignancies have started to emerge. Gemcitabine and irinotecan are well-tolerated single agents, each with a broad spectrum of antitumor activity. Preclinical data suggests synergy for the two drugs when used in combination. A phase I trial has defined a well-tolerated combination regimen using both drugs on a day-1, -8 schedule every 3 weeks. Phase II data suggest activity for the combination in pancreatic cancer, and a phase III trial of the two-drug combination versus gemcitabine alone is underway in previously untreated pancreatic cancer patients. Other phase II trials evaluating the impact of this combination on a variety of other tumors, such as non-small cell lung, small cell lung, breast, colorectal, and non-Hodgkin's lymphoma, are either forthcoming or in progress.

AB - Non-platinum combinations including gemcitabine and irinotecan (Gemzar; Eli Lilly and Company, Indianapolis, IN) for the management of a variety of malignancies have started to emerge. Gemcitabine and irinotecan are well-tolerated single agents, each with a broad spectrum of antitumor activity. Preclinical data suggests synergy for the two drugs when used in combination. A phase I trial has defined a well-tolerated combination regimen using both drugs on a day-1, -8 schedule every 3 weeks. Phase II data suggest activity for the combination in pancreatic cancer, and a phase III trial of the two-drug combination versus gemcitabine alone is underway in previously untreated pancreatic cancer patients. Other phase II trials evaluating the impact of this combination on a variety of other tumors, such as non-small cell lung, small cell lung, breast, colorectal, and non-Hodgkin's lymphoma, are either forthcoming or in progress.

UR - http://www.scopus.com/inward/record.url?scp=0034892564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034892564&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 34

EP - 43

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 10

ER -